PDCD1 and neoplasm: Conclusively, pharmacologically diminishing tumor cells stemness transformation by targeting the CDK5/pho‐PPARγ axis causes an obvious immunophenotyping shift, thus augmenting the efficacy of anti‐PD‐1 therapy in TNBC.